1042689
USP
Aripiprazole Related Compound F
United States Pharmacopeia (USP) Reference Standard
同義詞:
7-[4-[4-(2,3-Dichlorophenyl)-1-oxidopiperazin-1-yl]butoxy]-3,4-dihydroquinolein-2(1H)-one, 4-(2,3-Dichlorophenyl)-1-[4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyl]piperazin 1-oxide
About This Item
推薦產品
等級
pharmaceutical primary standard
API 家族
aripiprazole
製造商/商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
Clc1c(cccc1N2CC[N](=O)(CC2)CCCCOc3cc4c(cc3)CCC(=O)N4)Cl
InChI
1S/C23H27Cl2N3O3/c24-19-4-3-5-21(23(19)25)27-10-13-28(30,14-11-27)12-1-2-15-31-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
InChI 密鑰
ZNYNDJDSFMRJPS-UHFFFAOYSA-N
尋找類似的產品? 前往 產品比較指南
相關類別
一般說明
For further information and support please go to the website of the issuing Pharmacopoeia.
應用
- Aripiprazole
- Aripiprazole Orally Disintegrating Tablets
- Aripiprazole Tablets
分析報告
其他說明
相關產品
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
條款
Aripiprazole is an atypical antipsychotic and a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole was first approved by the U.S. Food and DrugAdministration in November 2002 for schizophrenia and by the European Medicines Agency in June 2004 for acute manic and mixed episodes associated with bipolar disorder.
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務